Revolution Medicines
A Senior Director, Epidemiology at Revolution Medicines leads epidemiology strategy and execution for oncology assets, working across clinical development, safety, medical affairs, and commercial teams to generate real-world evidence for patient care.
Headquarters
Redwood City, California, United States
Company Size
201-500 employees
Founded
2014
Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.
Victory Capital Management Inc. Trims Stock Holdings in Revolution Medicines, Inc. $RVMD
13 hours ago
Revolution Medicines Trials, Funding Capacity And Insider Moves Shape Risk Outlook
5 days ago
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Revolution Medicines.
135% above the average for this role
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs
1 week ago
Director, Epidemiology (Rare Oncology)
AstraZeneca
Senior Director, Respiratory Innovation, VID Global Epidemiology & RWE
GSK plc
Senior Director, Epidemiology
AstraZeneca
Senior Director, Epidemiology, Immunology
Celldex Therapeutics
Senior Director Safety Epidemiology
AstraZeneca
Director Epidemiology Respiratory
GSK plc